Sign in to view content

Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies

Jeffrey S. Heier, MD

Video
Published 2020

Related

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Updates from the Field
2019
Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2020
Single Intraoperative Subconjunctival Triamcinolone Acetonide Injection Versus 4-6-Week Topical Steroid Taper Following Vitreore
Elizabeth A Atchison, MD
Updates from the Field
2018

Category: Age-Related Macular Degeneration

See more